

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dorit Arad, et al.
 Serial No.: 09/202,359
 Confirmation No. 2806
 Filed: May 21, 1999
 Group: 1653
 Examiner: David Lukton
 For: **NOVEL ANTI-VIRAL COMPOUNDS**

Mail Stop ISSUE FEE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

18 February 2004
 (Date of deposit)

Karen L. Knezek
 Registration No. 39,253
 Name of Applicant, Assignee, or Registered Representative

Karen L. Knezek

Signature
 18 February 2004

Date of Signature

Dear Sir:

STATEMENT UNDER 37 C.F.R. §1.825

This statement is being filed pursuant to 37 C.F.R. §1.825. Applicants are filing concurrently herewith an amended Sequence Listing in paper copy and computer readable form attached as an Appendix to the Amendment under 37 C.F.R. §1.312.

The Sequence Listing has been amended to correct an error in SEQ ID NO:2. In the originally filed Sequence Listing, SEQ ID NO:2 is an 1-mer peptide having the sequence **Arg-Ala-Glu-Leu-Gln-Gly-Pro-Thr-Tyr-Asp-Glu**. The SEQ ID NO:2 in the amended Sequence Listing filed concurrently herewith has the sequence **Arg-Ala-Glu-Leu-Gln-Gly-Pro-Tyr-Asp-Glu**, wherein the "Thr" amino acid has been removed from the sequence.


The undersigned hereby states that, pursuant to 37 C.F.R. §1.825(a), the substitute sheets of the amended Sequence Listing in paper copy filed concurrently herewith include no new matter. Support for this change is given in the specification at Page 24, line 27 and at Page 26, line 11, where SEQ ID NO:2 is disclosed as Arg-Ala-Glu-Leu-Gln-Gly-Pro-Tyr-Asp-Glu, a 10-

mer peptide; and at Page 25, line 12, where SEQ ID NO:3, identified as the last 5-mer peptide upon cleaving the 10-mer peptide, has the sequence Gly-Pro-Tyr-Asp-Glu.

The undersigned hereby also states that, pursuant to 37 C.F.R. §1.825(b), the substitute copy of the Sequence Listing in computer readable form is identical to the Sequence Listing in paper copy filed concurrently herewith;

Applicants do not believe that a fee is required. However, if this is in error, any fee required by this document other than the issue fee, and not submitted herewith should be charged to Sidley Austin Brown & Wood LLP Deposit Account No. 18-1260. Any refund should be credited to the same account.

Respectfully submitted,



Karen L. Knezek
Registration No. 39,253

KLK:ld

February 18, 2004

SIDLEY, AUSTIN, BROWN & WOOD LLP

717 N. Harwood, Suite 3400

Dallas, Texas 75201

(214) 981-3381

(214) 981-3400 (fax)